For Q3 2025, net income attributable to KMI was $628 million and EPS was $0.28 per share. Adjusted net income and adjusted EPS grew 16% year-over-year, after excluding mark-to-market hedge impacts and ...
The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to ...
Panelists emphasize the complexity of choosing among available third-line therapies, noting that no single option fits all patients. Clinical decision-making weighs efficacy, safety, quality of life, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback